We are a COVID-19 Testing Facility

Are you or a loved one living with Small Cell Lung Cancer?

A clinical study for adults diagnosed with Small Cell Lung Cancer

Why is the IMP4297 study being done?

The purpose of this study is to find out about the safety and tolerability of IMP4297 in combination with temozolomide to determine if it is an effective treatment for solid tumors. IMP4297 is experimental, which means it is not approved by Health Authorities including the U.S. Food and Drug Administration (FDA) for the treatment of solid tumors. Temozolomide is a chemotherapy drug that is approved by the FDA for the treatment of brain cancer. 

Who can participate in the IMP4297 study?

You may be eligible to participate in this study if you:

Are age 18 and older

Have been diagnosed with Extensive Stage Small Cell Lung Cancer

Have received one and only one course of 1L standard platinum-based therapy

What happens during the study?

There are 5 study periods: screening, treatment, end of treatment, safety follow-up, and survival follow-up. All aspects of your participation will take place at the study location or at your place of residence. 






End of Treatment:


Safety Follow-Up:


Survival Follow-Up:

What treatment will I receive?

You will receive both IMP4297 and Temozolomide daily by mouth.

What tests will I have?

During the study, you may have tests to assess:

What else will I have to do?

Follow the study staff’s directions regarding the study

Will I receive compensation for participating in this study?

Yes, you will receive $150 upon your completion of the screening visit and $50 for each subsequent visit.

9730 S. Western Ave., Suite 218
Evergreen Park, IL 60805